Related Experiment Videos

MIB1 (Ki-67) expression in non-Hodgkin's lymphomas

A Kalogeraki1, M Tzardi, I Panagiotides

  • 1Department of Pathology University Hospital of Heraklion, Venizelion Hospital of Heraklion, Athens, Greece.

Anticancer Research
|January 1, 1997
PubMed

Insights

The MIB1 antibody reveals higher cell proliferation in high-grade non-Hodgkin

Area of Science:

  • Oncology
  • Immunohistochemistry
  • Cell Biology

Background:

  • Non-Hodgkin's Lymphomas (NHL) are a diverse group of cancers.
  • Accurate grading is crucial for predicting NHL behavior and guiding treatment.
  • Cell proliferation markers can aid in NHL classification and prognostication.

Purpose of the Study:

  • To investigate the utility of the MIB1 monoclonal antibody as a cell proliferation marker in non-Hodgkin's lymphomas.
  • To compare MIB1 expression levels between high-grade and low-grade NHLs.
  • To assess the potential of MIB1 index in predicting NHL biological behavior.

Main Methods:

  • Immunohistochemistry was performed on formalin-fixed, paraffin-embedded lymph node biopsy specimens.
  • 40 high-grade and 46 low-grade NHL cases, classified by the Kiel classification, were analyzed.
  • MIB1 staining intensity and patterns were evaluated in all cases.

Main Results:

  • All studied non-Hodgkin's lymphoma cases exhibited nuclear MIB1 staining.
  • A statistically significant difference (P < 0.005) in MIB1 expression was observed between high-grade and low-grade NHLs.
  • High-grade NHLs demonstrated a higher proliferation rate compared to low-grade NHLs, with notable variations within histological groups.

Conclusions:

  • The MIB1 index is a valuable tool for assessing individual tumor proliferation rates in non-Hodgkin's lymphomas.
  • MIB1 expression levels correlate significantly with NHL grade, distinguishing high- from low-grade tumors.
  • MIB1 index holds potential as a prognostic parameter when combined with clinical and laboratory data for non-Hodgkin's lymphomas.

Related Concept Videos